- In the News
Angus Russell has served as Chairman of the Board since March 2014. Mr. Russell is a veteran in the global biopharmaceutical industry with over 30 years of experience in commercial execution, operations, and strategic acquisitions. He has served on the Board of Directors at Mallinckrodt, since August 2014, BioTime, Inc. since December 2014, and TherapeuticsMD, Inc. since March 2015. Mr. Russell also served as a Director at Shire Plc from 1999 to 2013. During his tenure at Shire Plc, Mr. Russell served as CEO from 2008 to 2013 and CFO from 1999 to 2008. While CEO at Shire, Mr. Russell was also the Chair of Shire’s Leadership Team and a lead member of the Shire Management Committee, which designed and implemented Shire’s immensely successful long-term business strategy. Prior to joining Shire, Mr. Russell served at ICI, Zeneca, and AstraZeneca in various senior positions including VP of Corporate Finance at AstraZeneca. << CLOSE
Daniel Browne is a co-founder of the company and has served as our President, Chief Executive Officer and a member of the board of directors since operations commenced in 2002. Prior to joining Revance, Mr. Browne served as President and Chief Executive Officer of Neomend, Inc., a medical technology and biomaterials company; from 2001 to 2003 and from 1997 to 2000 he served as President of Prograft Medical Inc., both companies in the medical technology industry. Previously, Mr. Browne spent more than 16 years in various leadership positions in product development, sales and marketing and business development in the Gore Medical Products Division of W.L. Gore & Associates, Inc., a global technology company, serving as Business Leader in the Medical Products Division as his final role at the company. Mr. Browne holds a B.S. from the University of Hawaii in Cell and Molecular Biology and an M.B.A. from Pepperdine University. << CLOSE
Robert Byrnes has served as a director of our company since August 2004. Mr. Byrnes has spent over 40 years in the medical device and biotechnology industries. From October 1997 until October 2002, and again from January 2005 to the present, he has served as the President and Chief Executive Officer of Roan, Inc., an advisory service for healthcare organizations. From November 2002 to January 2005, Mr. Byrnes served as the President and Chief Executive Officer of Thermage, Inc., a medical device company focused on the non-invasive treatment of wrinkles. He has also served as Chairman and Chief Executive Officer of Tokos Medical Corporation, a health care services company, President of Caremark RX, Inc., a retail pharmacy and healthcare company, and Vice President of Marketing and Business Development for Genentech, Inc., a biotechnology company. Mr. Byrnes holds a B.S. in Pharmacy from Ferris State University and an M.B.A in Marketing and Finance from Loyola University, Chicago. << CLOSE
Mark Foley has served as a Board member of our company since September 2017. Mr. Foley has more than 25 years of operational and investment experience in the healthcare arena. He is currently Managing Director of RWI Ventures, a venture capital firm focused on life sciences, networking, semiconductor and software investments. Previously, Mr. Foley was Chairman, President and CEO of ZELTIQ Aesthetics (ZLTQ), serving from 2012 through the company’s acquisition in 2017 by Allergan (AGN) for $2.5 billion. During his tenure, he led ZELTIQ’s growth from $68 million in annual revenue in 2012 to over $350 million in 2016. Prior to ZELTIQ, Mr. Foley held a variety of senior operating roles in large public companies and venture-backed startups, including U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic) where he was the founder and CEO. He is a board member at Glaukos (GKOS) and also serves as Chairman of ULab and HintMD. Mr. Foley received a Bachelor of Arts degree from the University of Notre Dame. << CLOSE
Phyllis Gardner, M.D. has served as a director since December 2006. Dr. Gardner has spent over 35 years in academia, medicine and industry. She served as an adjunct Partner at Essex Woodlands, a growth equity firm that focuses on the healthcare industry, where she worked from June 1999 to 2014. Dr. Gardner has served on the board of directors of several public and private companies. She began her academic medical career at Stanford University, where she has held several positions, including Senior Associate Dean for Education and Student Affairs and she remains today as Professor of Medicine. From 1994 to 1996, she took a leave of absence from Stanford University to serve as Principal Scientist, Vice President of Research and Head of ALZA Technology Institute, a major drug delivery company. Dr. Gardner holds a B.S. from the University of Illinois and an M.D. from Harvard University. << CLOSE
Julian S. Gangolli has served as a director since July 2016. He is President, North America of GW Pharmaceuticals Inc., spearheading the buildout of the company’s U.S. commercial infrastructure in advance of the potential launch of its lead therapeutic candidate, Epidiolex® (cannabidiol or CBD), which is in late-stage development for a number of child-onset epilepsy syndromes. Mr. Gangolli is also a director of GW Pharmaceuticals PLC. Prior to joining GW Pharma, Mr. Gangolli served as President of the North American Pharmaceutical division of Allergan Inc. for 11 years, where he was responsible for a 1,400 person integrated commercial operation with sales exceeding $3.8 billion in 2014. Previously, he served as Senior Vice President, U.S. Eye Care at Allergan, during which time this division launched eight new products, helping to propel growth at more than 20% a year over a 5-year period. Prior to Allergan, Mr. Gangolli served in increasingly senior sales and marketing positions at VIVUS, Inc., Syntex Pharmaceuticals, Inc., and Ortho-Cilag Pharmaceuticals Ltd in the UK. Mr. Gangolli received a BSc (Honors) degree in Applied Chemistry and Business Studies from Kingston University in England. << CLOSE
Philip J. Vickers, Ph.D. has served as a director at Revance since February 2015. Dr. Vickers has spent over 25 years in the pharmaceutical industry and is currently Chief Executive Officer and board member at Northern Biologics Inc, a developer of first-in-class immuno-oncology products. From 2011 to 2017 he served as Global Head of Research and Development at Shire where he was responsible for overseeing preclinical research, clinical development, regulatory affairs, and medical affairs. Dr. Vickers was also a member of Shire’s Executive Committee and chaired the companies Pipeline Committee. Prior to Shire, he was Chief Scientific Officer and President at Resolvyx Pharmaceuticals, a biopharmaceutical company, from 2009 to 2011, where he was a member of the board of directors. Prior to Resolvyx, he served in various capacities with international biopharmaceutical companies including Boehringer-Ingelheim, Pfizer and Merck. Dr. Vickers was a Visiting Fellow at the National Cancer Institute in Bethesda, Maryland and holds a Ph.D. in Biochemistry from the University of Toronto, and a B.Sc. in Applied Biochemistry from the University of Salford, Manchester. << CLOSE
At Revance, careers and passion come together. We have assembled a team of highly motivated, talented industry professionals who challenge the status quo. Collectively, we aim to improve the patient’s treatment experience by changing the way drugs are delivered. This is no small task, but we believe it is possible. Our team works together each day to achieve that common goal.
We are seeking exceptionally experienced individuals who will immediately contribute to the rapid development of our ambitious product pipeline. Passion, creativity, and a dedication to developing products that improve lives and personal well-being are all a part of our culture.
As an entrepreneurial company, Revance combines a dynamic start-up culture with the structure and stability of a larger corporation. This allows employees to work on exciting projects and technology within an infrastructure that provides guidance and security.
Commitment to Customers: Our first priority is to the patients, doctors, nurses, and medical practitioners who use our products. We are focused on improving patient quality of life by developing, manufacturing, and marketing innovative therapeutic and aesthetic solutions.
Commitment to Employees: People are our most valuable asset. The company respects the passion, merit, and diversity that each individual brings to the organization. Employees have a duty to the team to operate at the highest standards of excellence, collaboration, and ethics.
Commitment to Shareholders: By capturing and expanding existing markets and creating new ones globally with our botulinum toxin therapies and other pharmaceuticals, we strive to provide superior returns to our investors.
Revance recognizes that our employees are the key to our success. We provide a comprehensive set of employee benefit programs that provide financial rewards and supports individual needs. Our benefits represent a value to our employees, above and beyond salary.
We provide the following:
RT002 injectable and RT001 topical are investigational product candidates. RT002 is currently undergoing clinical studies for both therapeutic and aesthetic indications. RT001 is in preclinical development.